References
- A
ltman , D. G., Lausen , B., Sauerbrei , W.,and Schumacher , M. 1994. Dangers of using “optimal” cutpoints in the evaluation of prognostic factor. Journal of the National Cancer Institute 86, 11, 829–835. - B
lanco , J. I. M., Bonilla , J. A. A., Homma , S., Suzuki , K., Fremont -Smith , P.,and de Las Heras , K. V. G. 2021. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – a retrospective observational study in elderly patients. Pulmonary pharmacology & therapeutics 67, 101989. - F
reedberg , D. E., Conigliaro , J., Wang , T. C., Tracey , K. J., Callahan , M. V., Abrams , J. A.,and Group , F. R. 2020. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology 159, 3, 1129–1131. - G
reiner , M., Pfeiffer , D.,and Smith , R. D. 2000. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Preventive veterinary medicine 45, 1–2, 23–41. - H
ogan II, R. B., Hogan III, R. B., Cannon , T., Rappai , M., Studdard , J., Paul , D., AND Dooley , T. P. 2020. Dual-histamine receptor blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients. Pulmonary pharmacology & therapeutics 63, 101942. - J
anowitz , T., Gablenz , E., Pattinson , D., Wang , T. C., Conigliaro , J., Tracey , K., AND Tuveson , D. 2020. Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalised patients: a case series. Gut 69, 9, 1592–1597. - L
iu , H., Yang , Y., Chen , C., Wang , L., Huang , Q., Zeng , J., Lin , K., Zeng , Y., Guo , P., Zhou , W.,and Liu , J. 2020. Reclassification of tumor size for solitary HBV-related hepatocellular carcinoma by minimum p value method: a large retrospective study. World journal of surgical oncology 18, 1, 1–10. - M
azumdar , M.and Glassman , J. R. 2000. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Statistics in medicine 19, 1, 113–132. - M
irkes , E. M., Coats , T. J., Levesley , J.,and Gorban , A. N. 2016. Handling missing data in large healthcare dataset: a case study of unknown trauma outcomes. Computers in Biology and Medicine 75, 203–216. - N
akamura , T. 1986. BMDP program for piecewise linear regression. Computer Methods and Programs in Biomedicine 23, 1, 53–55. - O
gura , T.and Shiraishi , C. 2022. Cutoff value for Wilcoxon-Mann-Whitney test by minimum P-value: application to COVID-19 data. International Journal of Statistics and Probability 11, 3, 1–8. - R C
ore Team . 2021. R Foundation for Statistical Computing. - R
eznikov , L. R., Norris , M. H., Vashisht , R., Bluhm , A. P., Li , D., Liao , Y. S. J., Brown , A., Butte , A. J.,and Ostrov , D. A. 2022. Identification of antiviral antihistamines for COVID-19 repurposing. Biochemical and biophysical research communications 538, 1, 173–79. - Ü
nözkan , H., Yilmaz , M.,and Dere , A. M. 2020. A stochastic approach to number of corona virus cases. Journal of Applied Mathematics, Statistics and Informatics 16, 2, 67–83. - V
ieth , E. 1989. Fitting piecewise linear regression functions to biological responses. Journal of applied physiology 67, 1, 390–396. - W
orld Health Organization . 2020. Coronavirus disease 2019 (COVID-19): situation report, 94. - W
orld Health Organization . 2022. Coronavirus disease (COVID-19). https://www.who.int/. - Z
ou , K. H., O’Malley , A. J.,and Mauri , L. 2007. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 115, 5, 654–657.